Prostate-Specific Membrane Antigen Use in Glioma Management: Past, Present, and Future.

Area of Science:

• Oncology
• Radiology
• Molecular Biology

Background:

• Prostate-specific membrane antigen (PSMA) is a metallopeptidase highly expressed in tumor neovasculature, including gliomas.
• PSMA's intracellular internalization capability makes it an attractive target for delivering therapeutics and radioligands.
• Targeting glioma neovasculature with PSMA is a growing area of research for diagnosis and management.

Purpose of the Study:

• To review the current applications of PSMA in glioma histopathology, imaging, and treatment.
• To explore the future directions for PSMA utilization in managing gliomas.

Main Methods:

• A literature review was conducted using PubMed and Scopus databases in June 2023.
• Search terms included "PSMA," "Prostate-Specific Membrane Antigen," "PSMA PET," and various glioma-related terms.
• Sixty-one relevant publications were selected from 94 screened articles for comprehensive analysis.

Main Results:

• PSMA PET imaging is a promising and accurate tool for glioma diagnosis and management.
• PSMA histopathology may serve as a predictive tool for glioma behavior.
• Preliminary data suggests potential usefulness of PSMA-targeted therapeutics in glioma treatment, though more studies are required.

Conclusions:

• PSMA PET imaging is effective for glioma diagnosis and management.
• PSMA histopathology shows potential in predicting glioma behavior.
• PSMA-targeted therapeutics warrant further investigation for glioma treatment efficacy.